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Abstract
Mild cognitive impairment is common in nondemented Parkinson’s disease (PD) patients and may
be a harbinger of dementia. In view of its importance, the Movement Disorder Society
commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD.
The proposed diagnostic criteria are based on a literature review and expert consensus. This article
provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The
criteria will require validation, and possibly refinement, as additional research improves our
understanding of the epidemiology, presentation, neurobiology, assessment, and long-term course
of this clinical syndrome. These diagnostic criteria will support future research efforts to identify
at the earliest stage those PD patients at increased risk of progressive cognitive decline and
dementia who may benefit from clinical interventions at a predementia stage.
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In Parkinson’s disease (PD) there is a spectrum of cognitive dysfunction, ranging from mild
cognitive impairment (MCI) to PD dementia (PDD). A Movement Disorder Society (MDS)
commissioned task force recently evaluated the literature pertaining to mild cognitive
impairment in PD (PD-MCI), and determined that MCI is common in nondemented PD
patients and is associated with increasing age, disease duration, and disease severity.1
Moreover, PD-MCI predicts the development of dementia, which can occur in up to 80% of
PD patients over the long term.2–4
There has been significant heterogeneity, however, in the definition of PD-MCI and the
clinical correlates predicting progression to PDD.1,5 A uniform definition of PD-MCI is
important, because it will help identify (1) the clinical characteristics of the earliest stage of
PD cognitive impairment, (2), the best predictors of conversion from PD-MCI to PDD, (3)
the effects of PD-MCI on quality of life and day-to-day functioning, (4) a well-characterized
patient population and a potential outcome measure for clinical trials, and (5) a useful
clinical entity that will allow clinicians, patients, caregivers, and researchers to communicate
better, thereby improving patient care and research efforts. Specific criteria for diagnosing
MCI in PD will enable clinicians and researchers to identify patients at increased risk of
developing PDD and who may benefit from early interventions. PD-MCI criteria may also
facilitate research aimed at determining disease pathogenesis in the earlier stages of disease.
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In view of the importance of early recognition of PD-MCI, the MDS Task Force has
delineated diagnostic criteria that include (1) characterization of the clinical syndrome and
(2) methods for its diagnosis. The proposed criteria are based on a literature review and
expert consensus. They will require validation and possibly refinement as additional
research improves our understanding of the epidemiology, presentation, neurobiology,
assessment, evolution, and treatment of PD-MCI.
Current Methods of Defining MCI
Different criteria for defining MCI in the general population have been proposed, and
several have undergone revision.6 MCI criteria by Petersen et al.7,8 require (1) a subjective
complaint of cognitive decline by the patient, preferably corroborated by a reliable source,
(2) minimal effect of the decline on day-to-day functioning and the absence of dementia, and
(3) evidence of cognitive abnormalities that cannot be simply attributed to age. Such
evidence can be based solely on clinician judgment, although formal neuropsychological
testing is deemed helpful. Specific neuropsychological tests and cut-off scores are not stated.
Quantitative measurements of function and activities of daily living are not required.
Categorization into single-domain, multiple-domain, amnestic, and nonamnestic subtypes is
based on the results of neuropsychological testing. Proposed MCI criteria recently
developed by the National Institute on Aging and the Alzheimer’s Association MCI criteria
committee6 and the DSM-5 Neurocognitive Disorders Work Group9,10 would also allow
cognitive decline to be detected by health care providers as an alternative to patient or
informant report.
Methodology
The MDS Task Force first reviewed literature on the epidemiology and phenomenology of
PD-MCI.1 In December 2010, the MDS Task Force participants held a 2-day in-person
meeting to critically review current knowledge on MCI in general and in PD specifically,
different PD-MCI subtypes, progression of PD-MCI to PDD, the neurobiology of PD-MCI,
the role for biomarkers in the diagnosis of cognitive problems in PD, and methods of
cognitive assessment. The primary objective of the task force was to develop criteria for PD-
MCI that would best differentiate these patients from those with normal cognition or
dementia. Participants summarized the information presented during group discussions and
submitted it to the task force chair (I.L.), who developed the initial manuscript draft. This
draft was reviewed and revised in an iterative process by the task force members between
January and June 2011, including an in-person meeting in June 2011. This article
summarizes the task force’s consensus.
PD-MCI Heterogeneity, Subtypes, and Dementia Risk
In its first review, the MDS Task Force concluded that PD-MCI is common in nondemented
patients (mean prevalence, 27%; range, 19%–38%) and is associated with the subsequent
development of PDD.1 The clinical profile of PD-MCI is heterogeneous, with a range of
cognitive domains affected. Overall, non-amnestic, single-domain impairment (i.e., any
single nonmemory domain) is the most common subtype of PD-MCI.1
Although few studies have evaluated the relationship between specific PD-MCI subtypes
and the development of PDD, there is preliminary evidence from prevalent cohorts that
nonamnestic single-domain MCI subtype,11 executive deficits,12–14 impaired verbal
fluency,13,15 visuospatial deficits,13 and memory and language dysfunction14,16 all predict
PDD. In a population-based, longitudinal study of incident cases, neuropsychological
features with a more posterior cortical basis were associated with incident dementia,
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whereas frontostriatally based deficits were not, thereby suggesting two distinct cognitive
syndromes with potentially different etiologies and prognoses.17
PD-MCI Criteria
PD-MCI is a syndrome defined by clinical, cognitive, and functional criteria (Table 1). The
proposed MDS Task Force criteria are rooted in the MCI criteria previously described, but
modified to address issues relatively specific to PD. The criteria were also designed to be
consistent with the MDS proposed PDD criteria and thereby allow transitions between
categories of normal cognition, MCI, and dementia.18,19 Similarly, the proposed PD-MCI
criteria utilize a two-level operational schema depending on the comprehensiveness of
neuropsychological testing.19 Level I and II categories both represent PD-MCI, but differ
regarding method of assessment, level of diagnostic certainty, and extent of clinical
characterization.
The criteria are also designed to be applicable to a range of populations, including patients
of different ethnic19 and educational backgrounds, and be reliable and valid for MCI
definition in clinical trials and longitudinal studies wherein MCI is an outcome measure or
an inclusion/exclusion criterion. The following sections outline proposed criteria for PD-
MCI, guidelines for level I and II diagnostic categories, and considerations entertained in
developing these criteria.
Inclusion Criteria
First, the diagnosis of PD20 must be clinically established (Table 1). PD-MCI is
characterized by an insidious decline in cognitive abilities caused primarily by the
underlying disease process. The cognitive decline may be reported by either the patient or
informant, or observed by the clinician. This allows for the greatest sensitivity in detecting
cognitive decline. Cognitive deficits should be present on testing, and specific
recommendations are presented for diagnosing PD-MCI with subtyping (Appendix A;
Tables 2 and 3). Finally, cognitive deficits should not interfere significantly with functional
independence.
Exclusion Criteria
Exclusion criteria include parkinsonism other than idiopathic PD, fulfillment of MDS
criteria for PDD, other plausible primary explanations for cognitive deterioration, and other
PD-associated comorbidities that, in the opinion of the clinician, may have significantly
influenced cognitive testing (see Table 1 for specific examples).
Specific Guidelines for PD-MCI Level I and Level II Categories
Level I (Abbreviated Assessment, Possible PD-MCI)—The level I category allows
for the diagnosis of PD-MCI based on an abbreviated cognitive assessment, because
comprehensive testing may not always be practical or available. Level I criteria provide less
diagnostic certainty than level II. The requirements for level I are impairment on a scale of
global cognitive abilities validated for use in PD (Table 2; and see cut-off guidelines for
global cognitive tests21–25) or impairment on a limited battery of neuropsychological tests
(e.g., including only one test per cognitive domain or those assessing fewer than five
cognitive domains). Identical to the MDS PDD operational criteria, the relevant cognitive
domains are attention and working memory as well as executive, language, memory, and
visuospatial functions (see Table 3 for examples of tests to assess these domains). When a
limited battery of neuropsychological tests is performed, impairment must be present on at
least two tests to diagnose PD-MCI by level I criteria. Level I criteria do not allow complete
subtyping of PD-MCI.
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Level II (Comprehensive Assessment)—For the diagnosis of PD-MCI by level II
criteria and PD-MCI subtyping, the task force recommends formal, comprehensive
neuropsychological testing that includes at least two tests for each of the five cognitive
domains previously listed. Impairment should be present on at least two tests, either within a
single cognitive domain or across different cognitive domains. Impairment on
neuropsychological tests may be demonstrated in several ways: performance between 1 to 2
standard deviations (SDs) below age, education, gender, and culturally appropriate norms,
significant decline on serial cognitive testing, or significant decline from estimated
premorbid levels. In a patient who does not score 1 SD below the normative mean but who
reports a change in cognition and has undergone serial neuropsychological testing, a
significant (i.e., at least 1 SD or exceeding the reliable change index [RCI]; Appendices B
and C)26 deterioration in cognition over time is acceptable to diagnose PD-MCI. The use of
two tests in each cognitive domain (minimum of 10 tests) for the level II category addresses
all cognitive domains equally, can increase sensitivity, and allow full subtyping of PD-MCI.
Subtype Classification for PD-MCI
Classification of PD-MCI subtypes is important for research purposes and to explore
whether impairments in different cognitive domains have a different neurobiological
substrate and course. To classify PD-MCI as single or multiple domain, comprehensive
neuropsychological testing with at least two tests per cognitive domain must be performed
(level II). Presence of two abnormal tests within a single cognitive domain, with the other
domains unimpaired, represents a single-domain subtype. If at least one test in two or more
cognitive domains is impaired, then PD-MCI should be subtyped as multiple domain. The
decision to require an impairment of at least one test in two or more cognitive domains for
PD-MCI multiple domain was based on previous studies22,27 that show that more stringent
requirements (i.e., a total of four abnormal tests, two tests in two domains) would
significantly decrease sensitivity to enhance specificity,28 which could adversely affect
epidemiological studies. The proposed criteria recommend specification of the affected
domain(s), rather than using amnestic or nonamnestic terminology, so that potential
differences among subtypes may be better studied. Examples of subtype designation would
be PD-MCI single domain (i.e., executive) or PD-MCI multiple domain (i.e., memory,
visuospatial). Appendix C gives examples of applications of PD-MCI criteria.
Discussion
Diagnostic criteria for PD-MCI are justified for several reasons. Recent studies in incident
and cross-sectional PD cohorts have revealed the extent and nature of cognitive dysfunction
in nondemented PD patients.1 Prospective studies to better understand the course, associated
features, and consequences of such cognitive deficits, as well as improved ways to
investigate therapeutic interventions in such patients, are underway. For research purposes,
uniform criteria will allow clearly defined patient populations to be included in such studies.
For clinical purposes, physicians and patients can use this designation to validate that
cognitive impairment exists, but not to the extent of being labeled dementia.
Terminology
The term MCI, as applied to the general population, denotes a state of impaired cognitive
function without attribution of underlying etiology.8 As such, MCI is a syndrome and, in
many patients, a transitional state. Other terms have also been used to define cognitive
impairment in nondemented patients.29 The task force chose to use the term PD-MCI, given
its current use in PD literature.
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Reports of Cognitive Decline
Empirical evidence to address how to best capture subjective reports of disability is
limited.30,31 Given these uncertainties, the task force criteria recommend the inclusion of
reports of cognitive decline made by either the patient, informant, or clinician observer to
increase the likelihood of capturing a change in cognitive function. However, PD patients
and their caregivers may both over- and underreport cognitive impairment,32 and
instruments that can reliably assess decline are needed.
To diagnose PD-MCI, cognitive decline should occur within the context of clinically
diagnosed PD. In some cases, however, the onset of mild cognitive impairment relative to
the motor symptoms is historically vague, and in other cases, cognitive symptoms occur
concurrently. In these scenarios, differentiating PD-MCI from incipient dementia with Lewy
bodies (DLB) can be challenging. More research is needed to establish the boundaries
between incipient DLB and PD-MCI. Careful clinical and neuropsychiatric assessments and
longitudinal evaluations will be needed to establish accurate diagnoses.
Absence of Significant Functional Decline
Existing MCI criteria do not specify how to document the absence of marked functional
decline (e.g., observation, interview, self-report, or rating scales), but emphasize the absence
of significant functional impairment resulting from cognitive impairment as the primary
feature that differentiates MCI from dementia. A broad survey of key functional areas, such
as management of medications19,33 or finances, should be considered, because impairments
in different cognitive domains of MCI may be associated with reduced performance in
different aspects of day-to-day functioning.34 There are challenges in separating
contributions of cognitive or motor deficits to functional tasks in PD, and this area requires
additional study.
PD-Associated Comorbidities
Mood disorders, apathy, psychosis,35 and rapid eye movement sleep behavior disorder
(RBD)36 are common in PD and may impair cognition or be associated with dementia
development.37 Moreover, anxiety and cognitive slowing during “off” periods can adversely
affect neuropsychological test performance.38,39 Thus, patients with motor fluctuations
should ideally be assessed in the “on” state, be devoid of anticholinergic medication (or
other drugs known to have an effect on cognition), and not have nonmotor features deemed
sufficiently severe to invalidate the results of the neuropsychological evaluation. It is the
responsibility of the person administering the neuropsychological instruments to judge the
extent to which such symptoms might interfere with the testing.
Although the task force maintains consistency with the MDS PDD criteria, in the proposed
PD-MCI criteria, the presence of prominent behavioral features, such as psychosis or severe
depression, preclude a reliable diagnosis of PD-MCI. Should these symptoms be present,
patients should be retested when they have improved or when symptoms have resolved.
Apathy may interfere with testing and frequently co-occurs with PDD. The clinician should
judge whether specific cognitive deficits exist in addition to apathy, or whether cognitive
impairment is only secondary to reduced motivation or effort. Furthermore, although
psychosis, RBD, and apathy have been associated with cognitive impairment or
development of PDD, there is insufficient evidence to recommend that the presence of these
symptoms strongly supports a diagnosis of PD-MCI.
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Cognitive Domains and Tests—Although assigning various cognitive tasks to domains
is somewhat arbitrary, it is critical for research purposes. The task force followed the general
conventions of clinical neuropsychology and cognitive neuroscience40,41 and of cognitive
research in PD in particular.5,42–45 Examples of tests used in PD for global cognitive
abilities and cognitive domains are provided (Tables 2 and 3).
The task force recommends the use of at least two tests in each cognitive domain for the
diagnosis of PD-MCI (level II). Though the optimal number of neuropsychological tests
within a given cognitive domain likely depends on the choice of tests and their sensitivity,
Schinka et al. demonstrated that the diagnosis of MCI based on two tests per domain is
probably more valid than when one test per domain is used.27 An excessive or imbalanced
number of tests per domain, however, might bias both diagnosis and subtyping of PD-MCI.
Additional research on the optimal number and type of tests per cognitive domain and how
this affects PD-MCI classification is needed. The recommendation to use two tests in each
of the five cognitive domains is particularly applicable to research studies, because this will
allow for full subtyping of PD-MCI and permit greater sensitivity in epidemiological
studies. It is anticipated that when sufficient research has been completed, the domains and
numbers of tests required for a diagnosis of PD-MCI may be modified to make it easier to
apply the criteria in clinical practice.
Assessment of Premorbid Functioning—Whether or not a patient is cognitively
impaired is judged against the background of his or her premorbid level of functioning, as
well as demographic corrections and the psychometric characteristics of the tests used. If
premorbid cognitive evaluation is available, test performance may be compared with
previous scores, taking into account measurement error, retest effects, and errors resulting
from multiple comparisons.
Information on handling measurement errors with RCIs is provided (see Appendix B).
Estimated premorbid levels may be based on demographic characteristics (e.g., education
level and occupation) and reading ability and vocabulary using tests such as the National
Adult Reading Test (NART) and Wechsler Test of Adult Reading (WTAR). These tests
allow reasonably accurate estimates of verbal intelligence and are quite insensitive to
cerebral deterioration in the absence of aphasia or marked dysarthria.
Following the DSM-5 draft criteria for a mild neurocognitive disorder,10 stronger evidence
of cognitive decline comes from having previous test data on patients. Consequently, the
task force advocates neuropsychological evaluation early in the course of PD to establish
baseline cognitive abilities.46 When such baseline data are available, subsequent scores
would ideally be compared to the baseline performance and converted to an RCI47 or similar
construct that considers test-retest reliability and potential practice effects.
Cutoffs for Neuropsychological Tests and Domains—Studies of MCI have
commonly utilized a range of cut-off scores at 1 to 2 SDs or more below the mean using
normative data. One issue in using a rigid cut-off score, such as −1.5 SD, is that high-
functioning people (e.g., those scoring at least 0.5 SD above the mean relative to an
appropriate normative sample premorbidly) would have to experience a decline of >2 SDs to
meet a −1.5-SD cutoff. Assuming a normal distribution of test scores, 30% of people scoring
0.5 SD or more above the mean premorbidly would not be detected as having experienced a
marked decline in cognition, even with a 1.5-SD decline in performance (i.e., false
negatives), whereas 7% scoring 1.5 or more SD below the mean premorbidly would be
falsely assumed to have cognitive decline, even without any change in performance over
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time (i.e., false positives). The requirement for impaired performance on at least two tests
reduces the risk for false positives, but not false negatives.
Differences in cut-off scores utilized have led to a wide range of prevalence estimates for
PD-MCI,32 and one study found that the best criterion to minimize the inclusion of
cognitively normal patients as having MCI was to require deficits of at least −1.5 SD in two
scores within any single domain (resulting in 30% PD-MCI) or deficits of at least −1.5 SD in
two scores from different domains (37% PD-MCI).28 The proposed PD-MCI criteria are
consistent with these cut-off scores,28 but because of potential differences among tests and
premorbid patient function, we propose a less-rigid recommendation of a range of 1 to 2
SDs below appropriate norms.
Motor Impairment and Neuropsychological Testing—Some of the recommended
neuropsychological tests contain relatively simple conditions that require timed motor
responses. Standard scores of these simple conditions may be used to take pure motor
slowing into account48 (Table 3). Nonetheless, it is recommended that patients be tested in
their optimal motor state, using tests that minimize motor demands.
Incorporation of Biomarkers in Criteria—Molecular and imaging biomarkers have
been studied in PD-associated cognitive impairment.17,49–56 Most studies, however, have
been small and have lacked detailed neuropsychological testing, prospective longitudinal
evaluations, and independently validated data. Therefore, the task force does not recommend
the inclusion of biomarkers as part of the PD-MCI criteria at this time, although future
validation of biomarker candidates is highly desired and may lead to revised criteria. An
anticipated biomarker for PD-MCI should be detectable at diagnosis, easily and widely
accessible, and validated in independent cohorts. There is a need for prospective,
longitudinal assessments of accessible biomarkers (including cerebrospinal fluid, blood, and
neuroimaging) that also incorporate neuropathological correlation. Though the National
Institute on Aging Alzheimer’s Association MCI criteria committee has incorporated
biomarkers into research criteria for MCI and Alzheimer’s disease, the field of PD has not
advanced sufficiently to consider biomarkers as criteria for cognitive decline at present.
To summarize, there are several differences between the diagnostic criteria proposed by the
MDS and other established criteria, such as Petersen’s original MCI criteria: (1) MCI is
defined within the context of an existing etiology, namely PD; (2) PD-MCI includes not just
“memory” complaints, but also other cognitive changes; (3) cognitive decline can be noted
by different sources; (4) PD-MCI must have deficits on either formal neuropsychological
testing or a test of global cognitive abilities; (5) specific level I and II categories are
outlined, including the number of domains, tests per domain, and cut-off scores suggested;
and (6) subtyping is recommended only for evaluations in which two neuropsychological
tests for each of the five domains are assessed and is strongly suggested for research
purposes.
In conclusion, the proposed MDS Task Force PD-MCI criteria provide a uniform method by
which to characterize and diagnose MCI in PD, providing a framework to advance our
understanding of the epidemiology, presentation, neurobiology, assessment, and treatment of
PD-MCI. Studies are needed to validate the proposed PD-MCI criteria, and further
refinement may be necessary as additional research on PD-MCI is conducted.
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TABLE 1
Criteria for the Diagnosis of PD-MCI
I. Inclusion criteria
• Diagnosis of Parkinson’s disease as based on the UK PD Brain Bank Criteria20
• Gradual decline, in the context of established PD, in cognitive ability reported by either the patient or informant, or
observed by the clinician
• Cognitive deficits on either formal neuropsychological testing or a scale of global cognitive abilities (detailed in section
III)
• Cognitive deficits are not sufficient to interfere significantly with functional independence, although subtle difficulties
on complex functional tasks may be present
II. Exclusion criteria
• Diagnosis of PD dementia based on MDS Task Force proposed criteria18
• Other primary explanations for cognitive impairment (e.g., delirium, stroke, major depression, metabolic abnormalities,
adverse effects of medication, or head trauma)
• Other PD-associated comorbid conditions (e.g., motor impairment or severe anxiety, depression, excessive daytime
sleepiness, or psychosis) that, in the opinion of the clinician, significantly influence cognitive testing
III. Specific guidelines for PD-MCI level I and level II categories
A. Level I (abbreviated assessment)
• Impairment on a scale of global cognitive abilities validated for use in PDa or
• Impairment on at least two tests, when a limited battery of neuropsychological tests is performed (i.e.,
the battery includes less than two tests within each of the five cognitive domains, or less than five
cognitive domains are assessed)
B. Level II (comprehensive assessment)
• Neuropsychological testing that includes two tests within each of the five cognitive domains (i.e.,
attention and working memory, executive, language, memory, and visuospatial)b
• Impairment on at least two neuropsychological tests, represented by either two impaired tests in one
cognitive domain or one impaired test in two different cognitive domains
• Impairment on neuropsychological tests may be demonstrated by:
– Performance approximately 1 to 2 SDs below appropriate norms or
– Significant decline demonstrated on serial cognitive testing or
– Significant decline from estimated premorbid levels
IV. Subtype classification for PD-MCI (optional, requires two tests for each of the five cognitive domains assessed and is
strongly suggested for research purposes)c
• PD-MCI single-domain—abnormalities on two tests within a single cognitive domain (specify the domain), with other
domains unimpaired or
• PD-MCI multiple-domain—abnormalities on at least one test in two or more cognitive domains (specify the domains)
a
See Table 2. Examples of scales of global cognitive abilities validated in PD.
b
See Table 3. Examples of neuropsychological tests for the five cognitive domains.
c
Subtype classifications are applicable only to those PD-MCI who have had at least two tests within each of the five cognitive domains
administered.
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TABLE 2
Examples of Neuropsychological Scales for Assessing Global Cognitive Abilities and Estimating Premorbid
Intelligence*
Assessment Neuropsychological Tests40 Estimated Time of Test, min
Global cognition MoCA22,58 10
PD-CRS24,59 15
SCOPA-COG59,60 15
MDRS23,59,61 20 to 30
Estimated premorbid intelligence NART40 5
WTAR40 5
Some of these tests are copyrighted and require permission from the authors to be used. The PD-CRS is a scale owned by the Movement Disorders
Society (see www.movementdisorders.org/publications/rating_scales/).
*
See also reference no. 57.
Abbreviations: MoCA, Montreal Cognitive Assessment; PD-CRS, Parkinson’s Disease-Cognitive Rating scale; SCOPA-COG, Scales for
Outcomes of Parkinson’s disease–Cognition; MDRS, Mattis Dementia Rating Scale.
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TABLE 3
Examples of Tests for Cognitive Domains and Estimated Time*




Attention and working memory WAIS-IV (or earlier version) Letter Number Sequencing 5
WAIS-IV Coding (or earlier version) or other substitution task, written or oral 5
Trail Making Testa 5 to 10
Digit span backward or digit ordering 5
Stroop color-word test 5 to 10
Executive function Wisconsin Card Sorting Test (CST), or modified CST (Nelson’s modification) 15
Tower of London test–Drexel version, or Stockings of Cambridge (CANTAB) 10 to 15
Verbal fluency test, such as letter fluency (COWAT or similar tests), category fluency
(animals, supermarket, or similar), or alternating fluency tasks (if a well-standardized
version is used). Not more than one verbal fluency test abnormality should be used to
satisfy the MCI criterion of two abnormal test performances because of the strong
relationship among these tests; 10 points Clock Drawing Test
5
Language WAIS-IV (or earlier version) Similarities 10 to 15
Confrontation naming task, such as Boston Naming Test (or short-form validated in PD)
or Graded Naming Test
5 to 15
Memoryb Word list learning test with delayed recall and recognition conditions, such as Rey’s
Auditory Verbal Learning Test, California Verbal Learning Test, Hopkins Verbal
Learning Test, and Selective Reminding Test
10 to 20
Prose recall3 test with a delayed recall condition, such as Wechsler Memory Scale-IV
Logical Memory subtest (or earlier version) or Rivermead Behavioural Memory Test
paragraph recall subtest
10 to 15
Brief Visuospatial Memory Test–Revised (BVMT-R) 10 to 15
Visuospatialc function Benton’s Judgment of Line Orientation 5 to 10
Hooper Visual Organization Test 10
Clock copying (e.g., Royall’s CLOX) 5
Two highly similar tests (e.g., two list learning tests or two story recall tests) should not be used to meet the MCI criterion of two test-score
abnormalities. Similarly, highly correlated scores from the same test (e.g., immediate and delayed recall of a word list) should not be used to meet
the criterion of two test abnormalities. Abnormality of two highly correlated scores only increases confidence in the existence of impairment.
*
See also reference no. 40 for references.
a
Trail Making Test (TMT) Part A, Stroop color-word subtests reading and color naming,48 may be used for this purpose. The TMT and Stroop
subtests are timed and give an estimate of manual and articulatory slowness that can be used to judge the significance of the more demanding
conditions (e.g., TMT-B, Stroop interference) or of other tests, such as fluency performance. Oral versions of neuropsychological tests may provide
alternatives.
b
In general, prose recall tests are relatively unreliable; therefore, one should administer at least two paragraphs.
c
Most visual memory tests are less appropriate for PD-MCI because these tests either require motor responses (e.g., drawing of geometric or other
figures) or evaluate recognition memory, which is less sensitive to early memory decline. BVMT-R is an exception because it allows for
assessment of the motor component via the copy condition.
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